Notice Regarding Business Alliance With BSMO Co., Ltd. and SBI Africa Co., Ltd.
1.2.2021 03:30:00 EET | Business Wire | Press release
BSMO Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tadashi Shimizu, hereinafter "BSMO") has announced today that BSMO has entered into a business alliance agreement with SBI Africa Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Tomoya Kitagawa, hereinafter "SBI Africa").
1. Background
As a pioneer in the field of SNS marketing, BSMO, through the best use of D2C x SNS marketing expertise and technology, provides one-stop growth hacking services for D2C e-commerce companies and helps deliver high-quality Japanese products and services to the world.
The population of Africa, where many emerging countries are located, is expected to double from 1.06 billion in 2019 to 2.11 billion people in 2050, according to the latest United Nations projections.
With the rapid population growth and economic growth in the African countries, the automobile usage rate is increasing every year which is driving a strong demand for reliable and affordable used cars from Japan.
By forming a business alliance with SBI Africa, which exports Japanese used cars to emerging countries, BSMO will introduce its D2C x SNS marketing expertise and technology to the SBI Group in order to strengthen the D2C exports in Africa, and thus improve the profitability and corporate values of both parties.
2. Details of the Business Alliance
(1) Improving the quality of SBI Africa's products and services by providing marketing research, advertising strategies, measurement strategies, design strategies, AI analytics, operations services and customer support services.
(2) Improving the profitability and brand value of both parties in the African region through joint sales of BSMO affiliated products and services on SBI Africa’s cross-border e-commerce website.
(3) Jointly providing system development and marketing strategy services for Japanese companies operating in Africa.
(4) Improving the profitability of BSMO and the marketing capabilities of SBI Group, through BSMO’s introduction of its marketing expertise and technology to SBI Group, etc.
[Company Overview]
|
Name |
BSMO Co., Ltd. |
|
Location |
1-17-1 Toranomon, Minato-ku, Tokyo Toranomon Hills Business Tower 14th floor |
|
Representative |
Tadashi Shimizu |
|
Business Description |
D2C marketing business, global growth hack business using SNS, branding business, media business, system development business, artificial intelligence (AI) development business, etc. |
|
Name |
SBI Africa Co., Ltd. |
|
Location |
1-6-1 Roppongi, Minato-ku, Tokyo Izumi Garden Tower 15F |
|
Representative |
Tomoya Kitagawa |
|
Business Description |
Overseas export business of domestic used cars, financial service provision business in partnership with overseas financial institutions, venture capital investment targeting the African region, etc. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005005/en/
Contact information
For inquiries regarding this press release:
BSMO Co., Ltd. +81-3-6459-5712
Ai Sena, Junko Nakahara
SBI Africa Co., Ltd. +81-3-6229-0086
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom